ESMO VIRTUAL ADVANCED COURSE PROGRAMME
CLINICAL QUESTIONS IN ADVANCED BLADDER AND RENAL CELL CARCINOMA
20-21 June 2022

CO-CHAIRS: Anja Lorch, Switzerland
Ravindran Kanesvaran, Singapore

SPEAKERS: Laurence Albiges, France
Richard Cathomas, Switzerland
Darren M. C. Poon, Hong Kong
Thomas B. Powles, United Kingdom
Manuela Schmidinger, Austria
Puay Hoon Tan, Singapore

LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of advanced bladder and renal cell carcinoma (RCC)
- To learn about state-of-the-art advances in treatment of advanced bladder and renal cell carcinoma
- To learn the principles of management of advanced bladder and renal cell carcinoma through direct exposure to real clinical scenarios

All timings are to be considered GMT+8 (Singapore Local Time)

Monday, 20 June 2022

15:00-15:05 Welcome and course overview
5’ Anja Lorch, CH
Ravindran Kanesvaran, SG

15:05-15:45 Session 1
State-of-the-art in Urothelial Cancer (UC) and Renal Cell Carcinoma (RCC) pathology and molecular pathology
(Chair/Moderator: Ravindran Kanesvaran, SG)

15’ Update in pathology and molecular pathology: RCC
Puay Hoon Tan, SG

15’ Update in pathology and molecular pathology: UC
Puay Hoon Tan, SG
10’  Discussion  
Faculty

15:45-15:55  Break

15:55-16:50  Session 2  
Management of mUC  
(Chair/Moderator: Anja Lorch, CH)

15’  Updates on 1st line management of mUC  
Richard Cathomas, CH

15’  2nd Line and Beyond: The art and science of sequencing treatments in mUC  
Thomas B. Powles, UK

15’  Adverse Effect (AE) management: New drugs, New AEs  
Darren M. C. Poon, HK

10’  Discussion  
Faculty

16:50-18:00  Session 3  
Management of mRCC  
(Chair/Moderator: Ravindran Kanesvaran, SG)

15’  Updates on 1st line management of mRCC  
Anja Lorch, CH

15’  2nd Line and Beyond: The art and science of sequencing treatments in mRCC  
Laurence Albiges, FR

15’  Updates on management of non-clear cell mRCC  
Manuela Schmidinger, AT

15’  AE management in mRCC  
Ravindran Kanesvaran, SG

10’  Discussion  
Faculty
Tuesday, 21 June 2022

15:00-15:40  Session 4
New treatments on the horizon
(Chair/Moderator: Ravindran Kanesvaran, SG)

15’ mUC: What's on the horizon — new treatments
Thomas B. Powles, UK

15’ mRCC: What's on the horizon — new treatments
Laurence Albiges, FR

10’ Discussion
Faculty

15:40-18:05  Workshops sessions
Three workshops sessions
15’ Introduction based on clinical cases presented by speakers
30’ Discussion

Workshop 1  Clinical cases in mUC
45’
Darren M. C. Poon, HK
Anja Lorch, CH

16:25-16:35  Break

Workshop 2  Clinical cases in mRCC (clear cell)
45’
Laurence Albiges, FR
Ravindran Kanesvaran, SG

Workshop 3  Clinical cases in mRCC (non-clear cell) and rare bladder cancers (e.g. adenocarcinoma)
45’
Thomas B. Powles, UK
Manuela Schmidinger, AT

18:05-18:10  Synthesis and wrap-up
Anja Lorch, CH
Ravindran Kanesvaran, SG